Related Experiment Video

Updated: May 14, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Ocrelizumab in early relapsing-remitting multiple sclerosis: first interim analysis of the MUSPO Italian prospective

Massimo Filippi1,2,3,4,5, Emanuele D'Amico6, Vincenzo Brescia Morra7,8

  • 1Neurology Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60 - 20132, Milan, Italy. filippi.massimo@hsr.it.

Journal of Neurology
|May 13, 2026
PubMed
Abstract

Insights

This study describes the baseline characteristics of early multiple sclerosis patients treated with ocrelizumab in Italy. The MUSPO cohort is young, mildly disabled, and provides a foundation for evaluating treatment effectiveness.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Research

Background:

  • Limited real-world data exists for ocrelizumab in early, minimally pretreated relapsing multiple sclerosis (MS).
  • Understanding patient characteristics is crucial for evaluating treatment outcomes.

Purpose of the Study:

  • To characterize the demographic, clinical, radiological, and treatment profiles of the MUSPO cohort.
  • To establish a baseline for longitudinal assessment of ocrelizumab effectiveness in Italian MS patients.

Main Methods:

  • Prospective, multicenter, observational study (MUSPO) enrolling adults with relapsing-remitting MS (RRMS) and rapidly evolving severe RRMS (RES).
  • Enrollment occurred ~6 months after ocrelizumab initiation, with MRI and cognitive assessments.
  • NEDA-plus (No Evidence of Disease Activity-plus) will be assessed longitudinally.

Main Results:

  • 199 patients (59 RRMS, 140 RES) were analyzed from 31 Italian sites.
  • Median Expanded Disability Status Scale (EDSS) was 2.0, indicating mild disability.
  • 29.6% had prior disease-modifying therapy (DMT) exposure; median time to ocrelizumab was 1.4 months.

Conclusions:

  • The MUSPO cohort represents a young, mildly disabled, early-treated population.
  • Comprehensive baseline MRI and limited prior DMT use support robust evaluation of NEDA-plus and effectiveness.
  • This study provides a strong foundation for real-world ocrelizumab effectiveness research in Italy.
Keywords:
NEDA-plusOcrelizumabRESRRMSReal-world evidence

More Related Videos

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...